Brendan M Everett1,2, M V Moorthy1, Jani T Tikkanen1, Nancy R Cook1, Christine M Albert1,3. 1. Divisions of Preventive Medicine (B.M.E., M.V.M., J.T.T., N.R.C., C.M.A.), Department of Medicine, Brigham and Women's Hospital, Boston, MA. 2. Cardiovascular Medicine (B.M.E.), Department of Medicine, Brigham and Women's Hospital, Boston, MA. 3. Department of Cardiology, Smidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA (C.M.A.).
Abstract
BACKGROUND: The majority of sudden cardiac deaths (SCDs) occur in low-risk populations often as the first manifestation of cardiovascular disease (CVD). Biomarkers are screening tools that may identify subclinical cardiovascular disease and those at elevated risk for SCD. We aimed to determine whether the total to high-density lipoprotein cholesterol ratio, high-sensitivity cardiac troponin I, NT-proBNP (N-terminal pro-B-type natriuretic peptide), or high-sensitivity C-reactive protein individually or in combination could identify individuals at higher SCD risk in large, free-living populations with and without cardiovascular disease. METHODS: We performed a nested case-control study within 6 prospective cohort studies using 565 SCD cases matched to 1090 controls (1:2) by age, sex, ethnicity, smoking status, and presence of cardiovascular disease. RESULTS: The median study follow-up time until SCD was 11.3 years. When examined as quartiles or continuous variables in conditional logistic regression models, each of the biomarkers was significantly and independently associated with SCD risk after mutually controlling for cardiac risk factors and other biomarkers. The mutually adjusted odds ratios for the top compared with the bottom quartile were 1.90 (95% CI, 1.30-2.76) for total to high-density lipoprotein cholesterol ratio, 2.59 (95% CI, 1.76-3.83) for high-sensitivity cardiac troponin I, 1.65 (95% CI, 1.12-2.44) for NT-proBNP, and 1.65 (95% CI, 1.13-2.41) for high-sensitivity C-reactive protein. A biomarker score that awarded 1 point when the concentration of any of those 4 biomarkers was in the top quartile (score range, 0-4) was strongly associated with SCD, with an adjusted odds ratio of 1.56 (95% CI, 1.37-1.77) per 1-unit increase in the score. CONCLUSIONS: Widely available measures of lipids, subclinical myocardial injury, myocardial strain, and vascular inflammation show significant independent associations with SCD risk in apparently low-risk populations. In combination, these measures may have utility to identify individuals at risk for SCD.
BACKGROUND: The majority of sudden cardiac deaths (SCDs) occur in low-risk populations often as the first manifestation of cardiovascular disease (CVD). Biomarkers are screening tools that may identify subclinical cardiovascular disease and those at elevated risk for SCD. We aimed to determine whether the total to high-density lipoprotein cholesterol ratio, high-sensitivity cardiac troponin I, NT-proBNP (N-terminal pro-B-type natriuretic peptide), or high-sensitivity C-reactive protein individually or in combination could identify individuals at higher SCD risk in large, free-living populations with and without cardiovascular disease. METHODS: We performed a nested case-control study within 6 prospective cohort studies using 565 SCD cases matched to 1090 controls (1:2) by age, sex, ethnicity, smoking status, and presence of cardiovascular disease. RESULTS: The median study follow-up time until SCD was 11.3 years. When examined as quartiles or continuous variables in conditional logistic regression models, each of the biomarkers was significantly and independently associated with SCD risk after mutually controlling for cardiac risk factors and other biomarkers. The mutually adjusted odds ratios for the top compared with the bottom quartile were 1.90 (95% CI, 1.30-2.76) for total to high-density lipoprotein cholesterol ratio, 2.59 (95% CI, 1.76-3.83) for high-sensitivity cardiac troponin I, 1.65 (95% CI, 1.12-2.44) for NT-proBNP, and 1.65 (95% CI, 1.13-2.41) for high-sensitivity C-reactive protein. A biomarker score that awarded 1 point when the concentration of any of those 4 biomarkers was in the top quartile (score range, 0-4) was strongly associated with SCD, with an adjusted odds ratio of 1.56 (95% CI, 1.37-1.77) per 1-unit increase in the score. CONCLUSIONS: Widely available measures of lipids, subclinical myocardial injury, myocardial strain, and vascular inflammation show significant independent associations with SCD risk in apparently low-risk populations. In combination, these measures may have utility to identify individuals at risk for SCD.
Authors: Paul M McKie; Denise M Heublein; Christopher G Scott; Mary Lou Gantzer; Ramila A Mehta; Richard J Rodeheffer; Margaret M Redfield; John C Burnett; Allan S Jaffe Journal: Clin Chem Date: 2013-04-16 Impact factor: 8.327
Authors: Juha H Vähätalo; Heikki V Huikuri; Lauri T A Holmström; Tuomas V Kenttä; M Anette E Haukilahti; Lasse Pakanen; Kari S Kaikkonen; Jani Tikkanen; Juha S Perkiömäki; Robert J Myerburg; M Juhani Junttila Journal: JAMA Cardiol Date: 2019-08-01 Impact factor: 14.676
Authors: Graham Nichol; Elizabeth Thomas; Clifton W Callaway; Jerris Hedges; Judy L Powell; Tom P Aufderheide; Tom Rea; Robert Lowe; Todd Brown; John Dreyer; Dan Davis; Ahamed Idris; Ian Stiell Journal: JAMA Date: 2008-09-24 Impact factor: 56.272
Authors: Eric C Stecker; Catherine Vickers; Justin Waltz; Carmen Socoteanu; Benjamin T John; Ronald Mariani; John H McAnulty; Karen Gunson; Jonathan Jui; Sumeet S Chugh Journal: J Am Coll Cardiol Date: 2006-02-23 Impact factor: 24.094
Authors: Brendan M Everett; Tanja Zeller; Robert J Glynn; Paul M Ridker; Stefan Blankenberg Journal: Circulation Date: 2015-03-30 Impact factor: 29.690
Authors: B Mihaylova; J Emberson; L Blackwell; A Keech; J Simes; E H Barnes; M Voysey; A Gray; R Collins; C Baigent Journal: Lancet Date: 2012-05-17 Impact factor: 79.321
Authors: Kumar Narayanan; Kyndaron Reinier; Carmen Teodorescu; Audrey Uy-Evanado; Ryan Aleong; Harpriya Chugh; Gregory A Nichols; Karen Gunson; Barry London; Jonathan Jui; Sumeet S Chugh Journal: J Am Heart Assoc Date: 2014-09-16 Impact factor: 5.501
Authors: Peter Willeit; Stephen Kaptoge; Paul Welsh; Adam Butterworth; Rajiv Chowdhury; Sarah Spackman; Lisa Pennells; Pei Gao; Stephen Burgess; Daniel Freitag; Michael Sweeting; Angela Wood; Nancy Cook; Suzanne Judd; Stella Trompet; Vijay Nambi; Michael Olsen; Brendan Everett; Frank Kee; Johan Ärnlöv; Veikko Salomaa; Daniel Levy; Jussi Kauhanen; Jari Laukkanen; Maryam Kavousi; Toshiharu Ninomiya; Juan-Pablo Casas; Lori Daniels; Lars Lind; Caroline Kistorp; Jens Rosenberg; Thomas Mueller; Speranza Rubattu; Demosthenes Panagiotakos; Oscar Franco; James de Lemos; Andreas Luchner; Jorge Kizer; Stefan Kiechl; Jukka Salonen; S Goya Wannamethee; Rudolf de Boer; Børge Nordestgaard; Jonas Andersson; Torben Jørgensen; Olle Melander; Christie Ballantyne; Christopher DeFilippi; Paul Ridker; Mary Cushman; Wayne Rosamond; Simon Thompson; Vilmundur Gudnason; Naveed Sattar; John Danesh; Emanuele Di Angelantonio Journal: Lancet Diabetes Endocrinol Date: 2016-09-03 Impact factor: 44.867
Authors: Ibrahim Akin; Michael Behnes; Julian Müller; Jan Forner; Mohammad Abumayyaleh; Kambis Mashayekhi; Muharrem Akin; Thomas Bertsch; Kathrin Weidner; Jonas Rusnak; Dirk Große Meininghaus; Maximilian Kittel; Tobias Schupp Journal: J Clin Med Date: 2022-05-25 Impact factor: 4.964